U-INCY

Q:INCY - INCYTE CORPORATION - http://www.incyte.com

05:02:48 EDT

Sym-X	Bid - Ask					Last	Chg	%Ch	Vol	$Vol	#Tr	Open-Hi-Lo	Year Hi-Lo	Last Tr	News	Delay
INCY - Q	0.3	81.45	·	84.60	0.1	82.68	-0.52	-0.6	999.2	82,621	15,074	83.62 83.869 81.52	110.365 75.52	18:55:18	Apr 13	15 min RT 2¢

Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
Nasdaq Indicators -- Market: Nasdaq -- Bid Tick: Down -- UPC Restricted: No

Fundamentals · Holders · Trade Workstation · Market Depth · 3 Month Closes · Technical Charts 1 yr | 3 yr | 5 yr | 10 yr | 15 yr | 20 yr · Live Charts 1 yr | 1 day · 1yr Bulletins · Historical · Options · Portfolio

Recent Trades - Last 10 of 15074

Time ET	Ex	Price	Change	Volume
18:55:18	Q	82.30	-0.90	65
18:55:18	Q	82.33	-0.87	65
17:24:23	Q	83.67	0.47	2
17:23:44	Q	82.70	-0.50	1
17:17:09	Q	82.67	-0.53	1
17:16:44	Q	83.67	0.47	2
17:15:46	Q	82.52	-0.68	1
17:15:15	Q	82.52	-0.68	1
17:15:14	Q	82.40	-0.80	100
17:15:14	Q	82.40	-0.80	340

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Date ET	Symbol	Type	Headline
2021-04-13 08:00	U:INCY	News Release200	Incyte to Report First Quarter Financial Results
2021-04-08 06:45	U:INCY	News Release200	Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients
2021-04-06 16:30	U:INCY	News Release200	Lilly and Incyte communicate review extension of supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis
2021-03-29 12:04	U:INCY	News Release200	Incyte Announces the European Commission Approval of Pemazyre ® (pemigatinib) as a Treatment for Adults with Locally Advanced or Metastatic Cholangiocarcinoma with a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion or Rearrangement
2021-03-23 05:13	U:INCY	News Release200	Incyte Announces Approval of Pemazyre ® (pemigatinib) in Japan for the Treatment of Patients with Unresectable Biliary Tract Cancer (BTC) with a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene, Worsening After Cancer Chemotherapy

Date ET

Symbol

Type

Headline

2021-04-13 08:00

U:INCY

News Release

Incyte to Report First Quarter Financial Results

2021-04-08 06:45

U:INCY

News Release

Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients